SIENDO: Oral Selinexor Maintenance After First-Line Chemotherapy in Advanced or Recurrent Endometrial Cancer Last updated on Aug 3, 2026 Previous SLND in Cervical Cancer Next GOG 92: Sedlis Criteria Study
